-
公开(公告)号：EP3586848A1
公开(公告)日：2020-01-01
申请号：EP18758340.6
申请日：2018-02-23
申请人： Daegu-Gyeongbuk Medical Innovation Foundation , National Cancer Center , Samsung Life Public Welfare Foundation
发明人： CHOI, Hwan Geun , PARK, Jong Bae , KO, Eunhwa , SON, Jung Beom , KIM, Nam Doo , LEE, Seung Hoon , NAM, Do-Hyun
IPC分类号： A61K31/505 , A61K31/506 , A61K31/437 , A61K31/415 , A61K31/519 , A61K31/5377 , A23L33/10
摘要： Disclosed is a pharmaceutical composition for the prevention or treatment of brain cancer, containing a compound capable of penetrating the blood-brain barrier as an active ingredient, the pharmaceutical composition for the prevention or treatment of brain cancer is capable of efficiently penetrating the blood-brain barrier of the brain to thereby effectively inhibit LRRK2 protein expression, and is thus useful in the prevention or treatment of brain cancer.
-
公开(公告)号：EP4105217A1
公开(公告)日：2022-12-21
申请号：EP21761078.1
申请日：2021-02-26
发明人： LEE, Doohyun , LEE, Seungyeon , HAN, Ye Ri , IM, Chun Young , KIM, So Young , KIM, Nam Hui , CHOI, Hwan Geun , KO, Eunhwa , MOON, Heegyum , LEE, Sun Joo , KIM, Sang Bum , KIM, Hyo-Ji , LEE, Sion , AHN, Sung-Min , CHANG, Kiho , LEE, Eunkyu , KWON, Hyun Jin , JEONG, Myeong-Sook , KIM, Ji Young
IPC分类号： C07D471/04 , A61K31/437 , A61K31/444 , A61K31/496 , A61P35/00 , A23L33/10
摘要： The present invention relates to a 3-((8-((1H-pyrazol-4-yl)amino)imidazo[1,2-a]pyridin-3-yl)ethynyl)-N-phenylbenzamide derivative, a method for preparing the same, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating cancer. The derivative can significantly inhibit the proliferation of cancer cells by inhibiting kinases, particularly Bcr-Abl kinase or Bcr-Abl (T315I) kinase. Therefore, the derivative can be effectively used as a pharmaceutical composition for the prevention or treatment of cancer.
-
公开(公告)号：EP3473624A1
公开(公告)日：2019-04-24
申请号：EP17815698.0
申请日：2017-06-20
发明人： CHOI, Hwan Geun , SON, Jung Beom , KIM, Shinae , LEE, Seungyeon , KO, Eunhwa , CHO, Joongheui , KANG, Seock Yong , KIM, So Young , PARK, Jin-Hee , KO, Yi Kyung , RYU, Hee Yoon , KIM, Nam Doo , KIM, Hyunkyoung , LEE, Younho , LEE, Sun-Hwa , KIM, Dayea , LEE, Sun Joo , HONG, Seongho , MIN, Sang Hyun , LEE, Sungwoo , CHOI, Dong Kyu , BAE, Jae Hyun , HONG, Eunmi , JANG, Tae-ho , SONG, Jaeyoung , KIM, Sangbum , YOON, Suk Kyoon
IPC分类号： C07D471/04 , A61K31/437 , A23L33/105
摘要： The present invention relates to a novel imidazopyridine derivative, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer. The novel imidazopyridine derivative according to the present invention, a stereoisomer thereof and a pharmaceutically acceptable salt thereof can effectively inhibit cancer-related kinases, are excellent in inhibiting proliferation of cancer cells in a cancer cell line, and effectively inhibit proliferation of cancer cells (cancer cell apoptosis) in a cancer cell heterograft model, and thus can be useful as a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer.
Also, the novel imidazopyridine derivative according to the present invention, the stereoisomer thereof, and the pharmaceutically acceptable salt thereof can effectively inhibit Src and Fyn, thereby being useful as a pharmaceutical composition for preventing or treating the Src and Fyn related diseases, and in particular, have been confirmed to be useful in diabetic nephropathy in animal model experiments. Therefore, the compound of the present invention can be effective as a pharmaceutical composition containing the same as an active ingredient for preventing or treating diabetic nephropathy.-
公开(公告)号：EP3604304A1
公开(公告)日：2020-02-05
申请号：EP18770572.8
申请日：2018-03-23
申请人： Daegu-Gyeongbuk Medical Innovation Foundation , Korea Research Institute of Bioscience and Biotechnology , Daegu Gyeongbuk Institute of Science and Technology
发明人： CHOI, Hwan Geun , KO, Eunhwa , CHO, Joong-heui , SON, Jung Beom , KO, Yi Kyung , PARK, Jin-Hee , KIM, So Young , KANG, Seock Yong , LEE, Seungyeon , RYU, Hee Yoon , KIM, Nam Doo , KIM, Sang Bum , LEE, Sun-Hwa , KIM, Dayea , LEE, Sun Joo , CHO, Sungchan , LEE, Kyu-Sun , YU, Kweon , CHOI, Miri , KOO, Ja Wook , HOE, Hyang-Sook
IPC分类号： C07D471/04 , A61K31/437 , A61K31/5377 , A23L33/10
摘要： The present invention relates to a pyrrolo-pyridine derivative compound, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for the prevention or treatment of protein kinase-related diseases. A compound represented by chemical formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, according to the present invention, has excellent inhibitory activity against various protein kinases including DYRK1A, and therefore, the pharmaceutical composition containing the same as an active ingredient can be favorably used in the treatment or prevention of protein kinase-related diseases. Particularly, the pharmaceutical composition can be effectively used in the prevention, treatment, or alleviation of Alzheimer's disease, dementia, or Alzheimer's dementia.
-
公开(公告)号：EP3587422A2
公开(公告)日：2020-01-01
申请号：EP18757481.9
申请日：2018-02-22
申请人： Daegu-Gyeongbuk Medical Innovation Foundation , National Cancer Center , Samsung Life Public Welfare Foundation
发明人： CHOI, Hwan Geun , PARK, Jong Bae , KO, Eunhwa , SON, Jung Beom , CHO, Joong-heui , KO, Yi Kyung , PARK, Jin-Hee , KIM, So Young , KANG, Seock Yong , LEE, Seungyeon , KIM, Nam Doo , LEE, Yunho , LEE, Sun-Hwa , KIM, Dayea , LEE, Sun Joo , BAE, Jae Hyun , HONG, Eunmi , JANG, Tae-ho , KIM, Sang Bum , LEE, Seung Hoon , NAM, Do-Hyun
IPC分类号： C07D487/04 , A61K31/519 , A61K31/5377 , A23L33/10
摘要： The present invention relates to a novel pyrrolo-pyrimidine derivative compound, a preparation method therefor, and a pharmaceutical composition comprising the same compound as an effective ingredient for preventing or treating a protein kinase-related disease. The compound represented by Chemical Formula 1 according to the present invention, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an effective ingredient has outstanding inhibitory activity against LRRK2 kinase and against phosphorylation in the NIH-3T3 cell line, which is an LRRK2-expressing cell line, and NCC01 and 448T cell lines, which are both derived from patients with brain tumors. Verified to have inhibitory activity against various protein kinases in addition to LRRK2, the compound can find effective applications in the treatment or prevention of protein kinase-related diseases.
-
-
-
-
搜索结果
5 条记录 (耗时 0.014 秒)
